Myelopoiesis in immunologically classified subgroups of childhood acute lymphocytic leukemia
โ Scribed by Crist, William M. ;Ragab, Abdelsalem H. ;Vogler, Larry ;Lui, Victor K. S. ;Castleberry, Robert P. ;Findley, Harry W. ;Merijanian, Greg
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- English
- Weight
- 405 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Soft agar culture studies of 43 immunologically characterized patients with childhood acute lymphocytic leukemia (ALL) are presented. The immunologic subsets studied include โnullโโcell, preโBโcell, and Tโcell leukemias. Abnormal myelopoiesis, including high peripheral blood and low marrow, colonyโforming cell numbers, low colonyโstimulating activity, and normal maturation of colonyโforming cells in vitro was noted in each group as previously described for immunologically uncharacterized ALL. We conclude that immunologic subsets of childhood lymphoblastic leukemia cause similar abnormalities of myelopoiesis. Lack of differences in growth characteristics among immunologic subsets of ALL make it impossible to use this tissue culture technique in subโclassification of these leukemic disorders.
๐ SIMILAR VOLUMES
We studied the karyotype in 81 consecutively diagnosed children with acute lymphocytic leukemia (ALL) treated at one institution on a randomized treatment protocol. In 75 patients (93%), a morphological cytogenetic result was obtained, and 57 (65%) were successfully G-banded. Of the 75 patients, 46
From the Divisions of Clinical Pharmacology and Toxicology (M.B., D.M., G. K.
## Abstract Until recently, Pneumocystis carinii pneumonitis was the most common cause of death in patients with leukemia in remission. Prior to the advent of effective antimicrobial agents, this disease was virtually 100% fatal in the cancer patient undergoing immunosuppressive therapy. The sponta
## Abstract The ability of intensive therapy, early in remission, to improve prognosis in childhood acute lymphocytic leukemia was tested in a randomized study. The intensive treatment included cyclophosphamide (200 mg/m^2^ IV weekly ร 4) and Adriamycin (40 mg/m^2^ IV weeks 1 and 3). These drugs we